RG6730 / Roche, Pfizer - LARVOL DELTA

A phase 1 study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of the p40xTL1A bispecific antibody PF-07261271 in healthy participants. (ECCO-IBD 2026) - "Conclusion PF-07261271 demonstrated p40 and TL1A target engagement and a favorable safety profile. Further studies are warranted to evaluate its safety and efficacy in patients with IBD."

Clinical • P1 data • PK/PD data • Inflammatory Bowel Disease • IL12A • TNFA

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of RO7837195 in Participants With Moderately to Severely Active Ulcerative Colitis (UC) (clinicaltrials.gov) - P2 | N=224 | Recruiting | Sponsor: Genentech, Inc. | Not yet recruiting ➔ Recruiting

Enrollment open • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of RO7837195 in Participants With Moderately to Severely Active Ulcerative Colitis (UC) (clinicaltrials.gov) - P2 | N=224 | Not yet recruiting | Sponsor: Genentech, Inc. | Trial completion date: May 2028 ➔ Oct 2028

Trial completion date • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of RO7837195 in Participants With Moderately to Severely Active Ulcerative Colitis (UC) (clinicaltrials.gov) - P2 | N=224 | Not yet recruiting | Sponsor: Genentech, Inc.

New P2 trial • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis